Evotec AG (EVT) – Financial and Strategic SWOT Analysis Review

Evotec AG (EVT) – Financial and Strategic SWOT Analysis Review Cover

Single Licence: $125

Buy Now
customer(s) bought this report
BUY WITH CONFIDENCE

Shopping on CFDMaster.com is Safe and Secure. GUARANTEED!
All information is encrypted and handled by PayPal.com

Need Assistance?
Have you got questions about this report? Why not speak to one of our advisors. Email us at business@cfdmaster.com or call us at +61 (02) 8011 3208
# Pages
Market
Country
Single User
Site License
Enterprisewide
62
Pharmaceuticals and Healthcare
Germany

Evotec AG (EVT) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

– Business description – A detailed description of the company’s operations and business divisions.
– Corporate strategy – Analyst’s summarization of the company’s business strategy.
– SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
– Company history – Progression of key events associated with the company.
– Major products and services – A list of major products, services and brands of the company.
– Key competitors – A list of key competitors to the company.
– Key employees – A list of the key executives of the company.
– Executive biographies – A brief summary of the executives’ employment history.
– Key operational heads – A list of personnel heading key departments/functions.
– Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
– Key manufacturing facilities – A list of key manufacturing facilities of the company.
– Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
– Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Evotec AG (Evotec) is a drug discovery alliance and development partnership company. It identifies and develops small molecule drugs across various therapeutic areas such as, cancer, neurological and nephrological conditions, cardiovascular, inflammation, pain, metabolic and respiratory diseases. Evotec provides services such as integrated services, assay development and screening, reagent production services, ADMET, cellular target profiling, vitro pharmacology services and proteomics services. Geographically, the company’s major operations are based in Abingdon, the UK; Gottingen and Munich, Germany; San Francisco and Branford, the US. Evotec is headquartered in Hamburg, Germany.

Evotec AG Key Recent Developments

Nov 12, 2014 Evotec reports results of the first nine months of 2014
Sep 30, 2014 Evotec receives milestone as part of its multi-target alliance with Bayer HealthCare
Sep 24, 2014 Evotec and Its Partners Awarded Public Grants to Develop New Drug Candidates to Treat Multiple Sclerosis
Sep 15, 2014 Evotec and the Jain Foundation expand collaboration Start of multiple drug screening programmes

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
– The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
– The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
– Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
– Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
– Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Table of Contents

Section 1 – About the Company 6
Evotec AG – Key Facts 6
Evotec AG – Key Employees 7
Evotec AG – Key Employee Biographies 8
Evotec AG – Major Products and Services 9
Evotec AG – Pharmaceutical Pipeline Products Data 10
Evotec AG, Pipeline Products by Therapy Area 10
Evotec AG, Pipeline Products by Development Phase 11
Evotec AG – History 14
Evotec AG – Company Statement 22
Evotec AG – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Section 2 – Company Analysis 25
Evotec AG – Business Description 25
Evotec AG – Corporate Strategy 26
Evotec AG – SWOT Analysis 27
SWOT Analysis – Overview 27
Evotec AG – Strengths 27
Strength – Comprehensive Range of Services 27
Strength – Focused R&D Activities 27
Strength – Strong liquidity 27
Evotec AG – Weaknesses 28
Weakness – Dependence on Few Customers 28
Weakness – Operational Performance 28
Evotec AG – Opportunities 29
Opportunity – Drug Discovery Outsourcing 29
Opportunity – Market Potential – Metabolic Disorders 29
Opportunity – Partnerships and Alliances 29
Opportunity – Strategic Acquisitions 29
Evotec AG – Threats 30
Threat – Government Regulations 30
Threat – Uncertain R&D Outcomes 30
Threat – Competitive Market 30
Evotec AG – Key Competitors 31
Section 3 – Company Financial Ratios 32
Financial Ratios – Capital Market Ratios 32
Financial Ratios – Annual Ratios 33
Performance Chart 35
Financial Performance 35
Financial Ratios – Interim Ratios 36
Financial Ratios – Ratio Charts 37
Section 4 – Company’s Lifesciences Financial Deals and Alliances 38
Evotec AG, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 38
Evotec AG, Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015 39
Evotec AG, Recent Deals Summary 40
Section 5 – Company’s Recent Developments 41
Nov 12, 2014: Evotec reports results of the first nine months of 2014 41
Sep 30, 2014: Evotec receives milestone as part of its multi-target alliance with Bayer HealthCare 45
Sep 24, 2014: Evotec and Its Partners Awarded Public Grants to Develop New Drug Candidates to Treat Multiple Sclerosis 46
Sep 15, 2014: Evotec and the Jain Foundation expand collaboration Start of multiple drug screening programmes 47
Sep 11, 2014: Evotec and CHDI Foundation extend ongoing collaboration to fight Huntington’s disease 48
Aug 19, 2014: Evotec and Medicines For Malaria Venture Announce a Long-Term Compound Management Collaboration 49
Aug 12, 2014: Evotec Reports Results of First Half of 2014 50
Jul 30, 2014: Evotec Receives First Milestones in TargetAD Collaboration 55
Jul 08, 2014: Evotec to collaborate with Fraunhofer in joint drug discovery programmes 56
Jun 23, 2014: Evotec receives European Mediscience Award for Best Communication 57
Section 6 – Appendix 58
Methodology 58
Ratio Definitions 58
About GlobalData 62
Contact Us 62
Disclaimer 62



List of Tables
Evotec AG, Key Facts 6
Evotec AG, Key Employees 7
Evotec AG, Key Employee Biographies 8
Evotec AG, Major Products and Services 9
Evotec AG, Number of Pipeline Products by Therapy Area 10
Evotec AG, Number of Pipeline Products by Development Stage 11
Evotec AG, Pipeline Products By Therapy Area and Development Phase 12
Evotec AG, History 14
Evotec AG, Subsidiaries 23
Evotec AG, Key Competitors 31
Evotec AG, Ratios based on current share price 32
Evotec AG, Annual Ratios 33
Evotec AG, Interim Ratios 36
Evotec AG, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 38
Evotec AG, Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015 39
Evotec AG, Recent Deals Summary 40
Currency Codes 58
Capital Market Ratios 58
Equity Ratios 59
Profitability Ratios 59
Cost Ratios 60
Liquidity Ratios 60
Leverage Ratios 61
Efficiency Ratios 61



List of Figures
Evotec AG, Pipeline Products by Therapy Area 10
Evotec AG, Pipeline Products by Development Phase 11
Evotec AG, Performance Chart (2009 – 2013) 35
Evotec AG, Ratio Charts 37
Evotec AG, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 38
Evotec AG, Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 39

Report Delivery

PDF SWOT Analysis Report An Electronic PDF copy of this Report will be sent to you via email.

Please allow up to 2 business days for the reports to arrive to your mailbox as some of our publishers prefer to send you the reports directly.

Purchase this Report today

Price: $125

Report Licences Explanation

* Single User: Electronic PDF copy delivered via email. Report can be used by individual purchaser only.

* Site License: Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.

* Enterprise Wide License: Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.

If you require a Site License or Enterprise Wide License please contact us to issue you an invoice.

Customers who Viewed this Report also Viewed

Risk warning: Your capital may be at risk. CFD trading is suitable for experienced traders and not beginners.